Navigation Links
MiMedx Group, Inc. to Present at Noble Financial Sixth Annual Equity Conference
Date:5/25/2010

MARIETTA, Ga., May 25 /PRNewswire-FirstCall/ -- MiMedx Group, Inc.  (OTC Bulletin Board: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it will present at the Noble Financial Sixth Annual Equity Conference in Hollywood, Florida.  William C. Taylor, President and Chief Operating Officer and Michael J. Senken, Chief Financial Officer of MiMedx, are scheduled to present on Monday, June 7, at 2:30 p.m. Eastern Time at the Hard Rock Hotel in Hollywood, Florida.  

The presentation will be webcast and available for viewing at www.mimedx.com on the "Investors" tab, or through the Noble Financial websites www.ontrack10.com, or www.nobleresearch.com. MiMedx recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. You will need the SiverLight viewer (a free download from presentation link) to participate. In addition, the webcast, transcript and written materials will be archived on the Company's website for 90 days following the even
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MiMedx Group Announces Temporary Trading Symbol Designation
2. MiMedx Group, Inc. Adds Ronald G. Wallace to Board of Directors
3. MiMedx Group Announces Post-split Name Change
4. MiMedx Announces Brian J. Splan as President
5. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
6. Encorium Group, Inc. Announces New Business Contract Wins of $6.8 Million, Including Two Pivotal Phase III Studies for a Major Asian Technology Company
7. Anpath Group, Inc. Announces Fiscal 2010 Third Quarter Results
8. Encorium Group, Inc. Announces One-for-Eight Reverse Stock Split
9. China YCT International Group, Inc. Announces That the State Intellectual Property Office of the Peoples Republic of China has Approved a Patent to its Operating Subsidiary, Shandong Spring Pharmaceutical Co. Ltd.
10. Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance
11. Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 1, 2015 ... announced the addition of the "Oxidative ... Services), Test Type (Indirect, Enzyme-based, Reactive Oxygen ... End Users - Global Forecast to 2020" ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , The ...
(Date:6/1/2015)... June 1, 2015 GenomeDx Biosciences ... analysis platform, successfully classified various subtypes of ... of certain biomarkers, including one type associated ... unique genomic signature has potential as a ... chemotherapy in patients with muscle-invasive bladder cancers ...
(Date:6/1/2015)... June 1, 2015  Novartis is highlighting data ... CTL019, an investigational chimeric antigen receptor (CAR) T ... treatment of specific types of hard-to-treat non-Hodgkin lymphoma. ... University of Pennsylvania,s Perelman School of Medicine (Penn) ... large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 Regis ... and manufacturing of chiral stationary phases (CSPs) for ... for its current and presenting solutions for new ... its portfolio. This valuable addition to its core ... effective advantage that can tackle projects for the ...
Breaking Biology Technology:Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3
... Blood ... Expertise, PALO ALTO, Calif., May 29 Pelikan Technologies ... announced the appointment of Dennert (Denny) Ware to its,board of ... of Kinetic Concepts, Inc. (KCI), a global medical,technology company, Mr. ...
... China, May 29 /Xinhua-PRNewswire-FirstCall/ -- China,Biologic Products, Inc. ... of the leading plasma-based pharmaceutical companies in the,People,s ... announced that the,Company has been approved by the ... commence the production of Human Albumin 12.5g/vial (25%,50 ...
... Clarient, Inc.,(Nasdaq: CLRT ), a premier ... oncologists and the pharmaceutical industry,today announced that, effective ... will join Clarient as Senior Vice President and ... years experience as a public,company CFO in life ...
Cached Biology Technology:Pelikan Technologies Appoints Denny Ware to Board of Directors 2Pelikan Technologies Appoints Denny Ware to Board of Directors 3China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml) 2China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml) 3Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer 2Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer 3Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer 4Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer 5
(Date:4/27/2015)... OXFORD, Conn. , Apr. 27, 2015 ... "Company"), a biometric authentication company focused on the growing ... will commence shipping to pre-order customers the first week ... pre-orders through the month of May. ... is a significant milestone for the company as Wocket® ...
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... 21 June, 2010 The Editors of the leading ... announce that the third Ahmed Zewail Prize in Molecular Sciences ... University of California, Berkeley, USA, for his outstanding contributions to ... monetary award of $20,000 and will be presented during the ...
... technology university, Nanyang Technological University (NTU), and Israel,s ... today announced a new collaboration to jointly offer ... The NTU-Technion Joint PhD degree programme is a ... Materials Science and Bioengineering. Significantly, the joint PhD ...
... Elsevier announced the launch of PeerChoice, a new pilot ... reviewers now have the freedom to choose which articles they ... and interest, efficiency and effectiveness of the peer review process ... three months, starting in June. PeerChoice reverses ...
Cached Biology News:Elsevier announces the winner of the Ahmed Zewail prize in molecular sciences 2NTU ramps up collaboration with Israel's top university 2NTU ramps up collaboration with Israel's top university 3Elsevier pilots PeerChoice in Chemical Physics Letters 2
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
... cyclin required for G1-phase progression and is ... cyclin D2 can phosphorylate pRB when associated ... Human, Mouse, and Rat. Others-not tested. ... suited for neutralization of cyclin D2 activity ...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Biology Products: